Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.

@article{Petrylak2015DocetaxelAP,
  title={Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.},
  author={Daniel Peter Petrylak and Nicholas John Vogelzang and Nikolay Budnik and Pawel Jan Wiechno and Cora N Sternberg and Kevin Doner and Joaquim Bellmunt and John M. Burke and Maria Ochoa de Olza and Ananya Sinha Choudhury and J{\"u}rgen Erich Gschwend and Evgeny Kopyltsov and Aude Fl{\'e}chon and Nicolas van As and Nadine Hou{\'e}d{\'e} and Debora Barton and Abderrahim Fandi and Ulf Jungnelius and Shaoyi Li and Ronald de Wit and Karim S Fizazi},
  journal={The Lancet. Oncology},
  year={2015},
  volume={16 4},
  pages={417-25}
}
BACKGROUND Patients with metastatic castration-resistant prostate cancer have few treatment options. We investigated the safety and efficacy of lenalidomide, an immunomodulatory agent with anti-angiogenic properties, in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. METHODS In… CONTINUE READING